AbbVie's Emraclidine Fails Phase II Trials, Impacting Shares and Boosting Bristol Myers Squibb

Emraclidine, a drug that showed promise in AbbVie's neuroscience portfolio, did not manage to outperform placebo in Phase II trials, focusing on treating schizophrenia[1][2]. These trials, which assessed changes in PANSS total scores, not only failed to achieve their primary endpoints but also revealed that placebo responses were unexpectedly high[2]. Despite the use of various control measures to address placebo effects, emraclidine’s performance did not surpass or was only on par with placebo results[3][2]. This failure has resulted in a significant impact on AbbVie's stock prices and has provided an edge to competitors such as Bristol Myers Squibb[1].